BioSpecifics Technologies Corporation
35 Wilbur Street
Lynbrook
New York
11563-2358
United States
Tel: 516-593-7000
Fax: 516-593-7010
Website: http://www.biospecifics.com/
219 articles about BioSpecifics Technologies Corporation
-
BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program
5/23/2019
BioSpecifics Technologies Corp. announced that the Executive Committee of its Board of Directors has authorized a stock repurchase program under which BioSpecifics is authorized to repurchase up to $4 million of its outstanding common stock.
-
BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results
5/10/2019
BioSpecifics Technologies Corp. announced its financial results for the first quarter ended March 31, 2019 and provided a corporate update.
-
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
4/2/2019
Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019
-
BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
3/18/2019
Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994.
-
BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development
11/15/2018
BioSpecifics Technologies Corp. today announced that Ron Law, Ph.D., J.D. has been appointed as Senior Vice President of Business Development and will be responsible for strategic partnerships, reporting directly to Thomas L. Wegman, President of BioSpecifics. Dr. Law has been consulting for BioSpecifics since July 15, 2018.
-
BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results
11/9/2018
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2018 and provided a corporate updat
-
BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids
10/31/2018
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum
-
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
8/30/2018
BioSpecifics Technologies Corp. today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences in September.
-
BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results
8/9/2018
Phase 1 trial of CCH for treatment of Uterine fibroids now fully enrolled
-
BioSpecifics Technologies Corp. Reports First Quarter 2018 Financial Results
5/9/2018
Continued year-over-year revenue growth for XIAFLEX
-
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results
3/14/2018
BioSpecifics reported net income of $2.6 million for the fourth quarter ended December 31, 2017.
-
BioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial Results
11/10/2017
Total revenue for the third quarter ended September 30, 2017 was $6.5M compared to $6.9M for the same period in 2016.
-
BioSpecifics Technologies Corporation Reports Second Quarter 2017 Financial Results
8/10/2017
-
BioSpecifics Technologies Corporation Reports First Quarter 2017 Financial Results
5/11/2017
-
BioSpecifics Technologies Corporation Initiates Phase I Clinical Trial Of XIAFLEX For Treatment Of Uterine Fibroids
4/18/2017
-
BioSpecifics Technologies Corporation Reports Fourth Quarter And Full Year 2016 Financial Results
3/15/2017
-
BioSpecifics Technologies Corporation Announces Positive Data From Phase 2b Study Of CCH In Patients With Cellulite
11/18/2016
-
BioSpecifics Technologies Corporation Reports Third Quarter 2016 Financial Results
11/10/2016
-
BioSpecifics Technologies Corporation To Report Third Quarter 2016 Financial Results On Wednesday, November 9, 2016
11/2/2016
-
BioSpecifics Technologies Corporation To Present At Two Upcoming September Conferences
9/2/2016